The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 09, 2024

Filed:

Dec. 14, 2018
Applicants:

The Board of Trustees of the University of Illinois, Urbana, IL (US);

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Inventors:

Ravishankar Krishnan Iyer, Champaign, IL (US);

Arjun Prasanna Athreya, Urbana, IL (US);

Richard Merle Weinshilboum, Rochester, MN (US);

Liewei Wang, Rochester, MN (US);

William Victor Bobo, Rochester, MN (US);

Mark Andrew Frye, Rochester, MN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G16B 40/00 (2019.01); G16C 20/30 (2019.01); G16B 40/20 (2019.01); G16B 40/30 (2019.01); G16H 50/00 (2018.01); G16B 20/00 (2019.01); G16C 20/70 (2019.01);
U.S. Cl.
CPC ...
G16B 40/00 (2019.02); G16B 20/00 (2019.02); G16B 40/20 (2019.02); G16B 40/30 (2019.02); G16C 20/30 (2019.02); G16H 50/00 (2018.01); G16C 20/70 (2019.02);
Abstract

The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention. The predictive methods may be augmented by metabolomics data, genomics data, or other objective measures taken from a patient, allowing the use of objective physiological measures to diagnosis and treat psychological conditions heretofore diagnosed and assessed using only subjective, self-reported measures.


Find Patent Forward Citations

Loading…